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Abstract 
 
In 1972, Sharp and colleagues described a new autoimmune rheumatic disease 
which they called mixed connective tissue disease (MCTD), characterized by 
overlapping features of systemic sclerosis (SSc), systemic lupus erythematosus (SLE), 
polymyositis/dermatomyositis (PM/DM), high levels of anti-U1snRNP and low 
steroid requirement use with good prognosis. MCTD was proposed as a distinct 
disease. However, soon after the original description, questions about the existence of 
such a syndrome as well as disputes over the features initially described began to 
surface. The conundrum of whether MCTD is a distinct disease entity remains 
controversial. We undertook a literature review focusing on the articles reporting new 
data about MCTD published in the last decade, to determine whether any new 
observations help to answer the conundrum of MCTD. After reviewing recent data, 
we question whether the term MCTD is appropriately retained, preferring to use the 
term “undifferentiated autoimmune rheumatic disease”. 
 
 
 
 
 
1 
 
Mixed Connective Tissue Disease– Enigma Variations? 
 
 
Introduction 
 
Over forty years ago mixed connective tissue disease (MCTD) was envisaged as a 
condition characterized by high levels of antibodies to ribonucleoprotein (RNP), 
Raynaud’s phenomenon, swollen fingers, esophageal dysfunction and the absence of 
lung and renal disease. These patients required low steroids and the prognosis was 
good[1]. Within ten years, major doubts about the original claims emerged. Nimelstein 
et al[2] in reviewing the original 25 cases observed that some patients lacked high levels 
of anti-RNP, and three could not be identified. Furthermore lung and renal disease 
occurred, the steroid requirement could be high and the prognosis seemed closer to that 
of lupus patients. These and other data reviewed elsewhere[3],[4] led to major doubts 
about MCTD as originally defined and as a separate disease entity.  
 
There have been four attempts to develop classification criteria and the conundrum 
of whether MCTD should be renamed continues. Here, we focus on the literature 
published about ‘MCTD’ in the past decade. We sought to discover if any genuinely 
original insights have emerged to help unravel the MCTD mystery.  
 
Methodology 
 
Our literature review focused on articles in English published from 2005-2015. We 
identified 479 articles listing MCTD or anti-RNP as key words. We excluded case 
reports and articles focusing on undifferentiated connective tissue disease (UCTD) but 
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did not really consider MCTD at all. Around 100 articles remain, which formed the 
basis of this review.  
 
Diagnostic Criteria& Disease Evolution 
 
 Four sets of classification criteria for MCTD have been published: Sharp’s[5], 
Kasukawa’s[6], Alarcon-Segovia’s[7], and Kahn’s[8]. Previous literature concluded that 
those of Alarcon-Segovia had the highest sensitivity and specificity, while Sharp’s 
criteria had a lower specificity[9],[10]. One recent study[11] evaluated 161 MCTD 
patients at diagnosis and after a mean follow up of 7.9 years observing their evolution. 
Kasukawa’s criteria were more sensitive (sensitivity 75%) compared to 
Alarcón-Segovia’s (73%) or Sharp’s (42%) criteria. The percentage of patients at final 
follow up who satisfied 1 or more of the 3 classification criteria was lower compared to 
the time at diagnosis (Kasukawa: 53% versus 75%; Alarcon: 44% versus 73%; Sharp: 
32% versus 42%). Even using Kasukawa’s criteria >40% were no longer diagnosable as 
having MCTD. Of the remainders, 17.3% evolved into systemic sclerosis (SSc), 9.1% 
into systemic lupus erythematosus (SLE), 2.5% into rheumatoid arthritis (RA) and 
11.5% were reclassified as UCTD. The percentage of patients evolving into other 
autoimmune rheumatic diseases (ARDs) was lower in patients with disease duration of 
0-5 years than in those >5 years. Using multiple variable regression, a significant 
association was found between anti-dsDNA at the first visit and evolution into SLE in 
those initially diagnosed with MCTD by Kasukawa’s criteria (OR 1.3; P=0.012) and 
Alarcón-Segovia’s (OR 1.4; P=0.001). In patients with a first diagnosis of MCTD 
(Kasukawa’s criteria), sclerodactyly (OR 1.2; P=0.034) and esophageal hypomotility or 
dilation (OR 1.4; P=0.001) were associated with evolution into SSc. 
3 
 
 
Another study[12] reported that the point prevalence showed no statistical difference 
between the three criteria sets (Sharp’s, Alarcón-Segovia’s or Kasukawa’s), indicating 
that they may be comparable[12]. The point prevalence of MCTD in living adults in 
Norway was 3.8 per 100 000, while the incidence of adult-onset MCTD in Norway 
from 1996-2005 was 2.1 per million per year. 
 
 A study[13] involving 280 MCTD patients reported different disease evolution 
observations. During follow-up, MCTD patients developed new symptoms; but did not 
show progression to other ARDs. This finding contrasted markedly with earlier studies, 
which demonstrated that most patients with anti-U1RNP developed into classified 
ARDs within 5 years of presentation. In these studies, Sharp’s criteria were often used, 
which may be less specific than other criteria[14],[15]. In other reports, the 
classification criteria used for diagnosis were not confirmed[16], which might have 
influenced the evolution rate.  
 
Clinical Features (Table 1 summarizes new findings in recent 10 years) 
 
Pulmonary hypertension  
 
 Pulmonary hypertension (PH) is a major clinical feature in MCTD, with 
prevalence from 10%to 50%. There are three recent prevalence studies. In one, PH 
occurred at a frequency of 3.4%[17]. In the others, the prevalence of pulmonary arterial 
hypertension ranged from 14% to 17.9% in MCTD[13],[18]. PH associated with ARDs 
is classified into five subgroups:[19] 
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• Group 1: pulmonary arterial hypertension (PAH); 
• Group 2: PH due to left heart disease; 
• Group 3: PH due to lung disease or hypoxia; 
• Group 4: chronic thromboembolic pulmonary hypertension (CTEPH); 
• Group 5: PH with unclear or multifactorial mechanisms. 
Thus, PAH is just one subgroup in PH. The 3.4% prevalence of PH in the nationwide 
Norwegian multicentre cohort of 147 adult MCTD patients included isolated PAH and 
PH due to interstitial lung disease (ILD)[17]. The lower than anticipated PH prevalence 
was possibly explained by the selection of the study population. While previous studies 
usually assessed PH in MCTD referred to tertiary centres, this study screened 
unselected MCTD patients throughout Norway, perhaps leading to a lower prevalence. 
Different studies have used different cut offs on echocardiograms to screen for PH 
before subjecting the patients to right heart catheterization (RHC). One used pulmonary 
artery systolic pressure (PASP) of >40 mmHg as a cut off[17], while two others used 
right ventricular systolic pressure (RVSP) of 25 mmHg for screening[13],[18]. PASP is 
considered equal to RVSP in the absence of pulmonary outflow tract obstruction. This 
discrepancy might significantly affect the ascertainment rate for PH.  
 
 Anti-U1RNP, anti-antiendothelial cell (AECA), anticardiolipin antibodies (ACL) 
and IgG anti-beta-2-glycoprotein I (anti-β2-GPI) might be associated with development 
of PAH; suggested by higher levels of these antibodies in MCTD patients with PAH 
compared to those without. AECA were also associated with high serum 
thrombomodulin and von Willebrand Factor antigen (vWFAg) levels, indicating 
endothelial cell activation and damage[13],[18],[20]. Furthermore, anti-U1RNP might 
have a direct pathogenic role. Considering antiphospholipid antibodies, previous studies 
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showed that ACL were not associated with thromboembolism in MCTD, and most ACL 
in MCTD sera are beta-2-glycoprotein I independent, which may explain the absence of 
associated clotting events[21],[22]. However, as MCTD-PAH patients tended to have 
higher levels of antiphospholipid antibodies[13],[20], suggesting their potential role in 
PAH. PAH in MCTD was noted to be more commonly associated with Raynaud’s 
syndrome with abnormal nailfold capillaroscopy[23]. 
 
In MCTD, diastolic function of left ventricle was worse compared to a control 
group. For right ventricular function, there was global failure of the right ventricle 
function in cases of MCTD complicated with PAH, while right ventricle function in 
those without PAH was not different from the controls[24]. 
 
The pathophysiology of PAH in MCTD is similar to other ARDs, especially SSc. 
But interstitial lung disease (ILD) was not significantly related to PAH in 
MCTD[25],[26]. Among ARDs with associated PAH, one-year survival and discharge 
from hospital were lower in MCTD with PAH when compared to SLE, SSc and RA 
with PAH[27]. One recent review recommended that all patients with SSc, CREST 
syndrome, or MCTD should undergo annual screening with echocardiography for PAH, 
though RHC is the standard for definitive diagnosis. Cardiac MRI is complementary for 
diagnosing PAH[28].  
 
Interstitial lung disease 
 
 Two studies involving more than 100 MCTD patients showed that 47.1% and 52% 
had evidence of ILD[13],[29]. Another study evaluated ILD and esophageal dysfunction 
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and reported HRCT abnormalities in up to 78 % among 50 MCTD patients[30]. 19% 
had severe lung fibrosis, these patients had lower functional status. The mortality was 
significantly worse in severe lung fibrosis. These patients had shorter mean disease 
duration at study inclusion than patients with minor or moderate fibrosis, indicating a 
more rapidly progressive disease[29]. 
 
 Concerning ILD in MCTD, the most frequent histology is non-specific interstitial 
pneumonia (NSIP), followed by usual interstitial pneumonia (UIP) and lymphocytic 
interstitial pneumonia (LIP)[28]. Anti-U1RNP antibodies may contribute to disease 
manifestations. They induce pulmonary injury in murine models[31],[32]. A correlation 
was found between diffusing capacity for carbon monoxide (DLCO) and ILD, but not 
between total lung capacity and ILD[30]. This is probably because reduced DLCO is the 
most sensitive test for predicting ILD. Esophageal abnormalities may also be related to 
ILD. In MCTD, 3 different sub-phenotypes can be seen: 
1st subgroup: AECA and antiphospholipid antibodies associated with PAH, Raynaud’s, 
livedo reticularis and vascular thrombosis. 
2nd subgroup: presence of ILD, esophageal dysmotility and myositis. 
3rd subgroup: higher prevalence of anti-CCP antibodies and erosive arthritis 
In cluster 2, the incidence of ILD was 98.7%, significantly higher than in groups 1 and 3 
(p<0.001). Nailfold capillaroscopy might help to differentiate the subgroups, as 
abnormal scleroderma like capillary pattern was found most commonly in the first 
subgroup (68.7% vs 26.5% and 33.3% in the other two subgroups). This SSc capillary 
pattern also correlated with ACL, AECA (p<0.0001) and PAH (p<0.05). The worst 
overall survival probability belonged to cluster 1, where 11 of 17 patients died, eight 
from PAH[33].  
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Esophageal involvement 
 
 64% of MCTD patients had severe esophageal dysfunction, and 50% of patients 
had distal abnormal acid reflux. However, there was no statistically significant relation 
between esophageal dysfunction and acid reflux. ILD was significantly higher among 
patients with esophageal dilatation (92% vs. 45%; p<0.01) and severe esophageal 
dysfunction (90% vs. 35%; p<0.001). No statistically significant differences in the 
frequencies of ILD between patients with normal or abnormal acid reflux were 
found[30], i.e. there was correlation between severe esophageal dysfunction and lung 
damage in the absence of acid reflux. Thus ILD may be associated with food reflux 
instead of acid reflux in MCTD. This observation was reminiscent of another study 
demonstrating abnormal lung function tests and significant delay in the clearance of the 
nucleotide in the scintigraphy[34]. 
 
Musculoskeletal involvement 
 
Arthritis in MCTD has a possible association with rheumatoid factor (RF) and 
anti-CCP. Whereas RF was positive in 30 to 100% of MCTD patients, anti-CCP was 
found in only 9%. Anti-U1RNP may be a predictor of more aggressive erosive 
arthritis[22]. Recent observations[35] included significantly higher levels of serum 
IgM-, IgG- and IgA-RF in MCTD patients when compared with controls(p<0.05). The 
frequency of IgM-RF in MCTD patients was 48% vs. 77% in RA. A recent review[36] 
reported 75-95% MCTD patients had arthritis. Around 50% of patients with frank 
arthritis are erosive. HLA-DR4 is associated with polyarthritis in MCTD. 
8 
 
 
 There have been no major new observations of myositis in MCTD. Up to 2/3 of 
MCTD patients have overt myositis ranging from mild to severe[22]. When myositis 
patients with anti-RNP antibodies were compared to those without, the former group 
responded better to corticosteroids. Histologically, myositis in MCTD is 
indistinguishable from dermatomyositis (DM). Immunoglobulin deposits were found in 
muscles and it is an immune-complex-driven disease[25],[37],[38]. 
  
Cardiovascular involvement 
 
 The prevalence of cardiac involvement varies from 13% to 65%[39]. Pericarditis 
was the most common cardiac diagnosis with prevalence of 30% and 43% in 2 
prospective studies. Non-invasive cardiac tests detected subclinical cardiac 
abnormalities in 6%–38% of patients. Diastolic dysfunction and accelerated 
atherosclerosis were well-documented in a case–control study[24]. Two older and one 
recent prospective studies revealed an overall mortality of 10.4% over an ensuing 13–15 
years. 2.1% of patients died of direct cardiac causes[13],[40],[41]. 
 
 Endothelium-dependent vasodilation, assessed by flow-mediated dilation (FMD), 
was significantly impaired in MCTD (Alarcón-Segovia’s criteria) versus controls[42]. 
The percentage of FMD was even lower in MCTD with cardiovascular diseases (CVD), 
than in those without it. The percentage of nitrate-mediated dilation (NMD) did not 
differ between MCTD vs. controls, and MCTD patients with CVD vs. those without. 
Mean carotid intima-media thickness (IMT) was higher in MCTD patients than in 
controls. 
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Renal involvement 
 
 The original MCTD description stressed the paucity of renal involvement[1] but 
later review showed that it occurred with a frequency between 5% and 36%[43].In one 
review[44], 12 of 30 MCTD patients (40%) had renal involvement. The majority had 
membranous glomerulonephritis (GN), followed by mesangial GN. Some patients had 
proliferative GN and a few had scleroderma pattern[45]. Patients with renal disease 
have more systemic manifestations than those without. 72% of nephropathy patients 
experienced resolution or improvement with steroids. Electron microscopy revealed 
immune complex deposition in the glomeruli[36][44]. In MCTD patients, the 
anti-U1snRNP seemed to have no correlation with nephropathy[44]. But in a study of a 
murine model[46], immunization of mice with RNP antigen induced anti-RNP and 
MCTD clinical manifestations, typically ILD but not renal disease. In contrast, for mice 
deficient in Toll-like receptor 3 (TLR-3), RNP antigen exposure induced SLE-like GN. 
Exposure to RNP antigen in an appropriate context may induce autoimmunity and 
MCTD features, while changes in innate immunity or TLR signaling with the same 
trigger may lead to the development of SLE-like nephritis. 
 
Raynaud’s phenomenon (RP) & capillaroscopy 
 
 Capillaroscopy findings of nailfold capillaries are usually classified as normal, 
nonspecific, or scleroderma (SD) like. The prevalence of RP observed in scleroderma 
and MCTD is generally 90% or more in most studies. There are 2 different types of SD 
pattern:  
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1)Slow: Irregularly enlarged or giant loops with no or minimal capillary loss  
2)Active: Definite capillary loss and neoformation of capillaries.  
MCTD patients often demonstrate a slow SD pattern. RP tends to be less severe in 
MCTD than in scleroderma, with fewer digital ulcers or loss of digits[47]. 
 
In a recent prospective study enrolling over 3000 patients with primary RP, initially 
none of the patients with primary RP had symptoms or signs of ARDs and all had 
normal nailfold capillaries. After a mean FU of 4.8 years, 1,660 (54.8%) patients still 
had primary RP, but 246 (8.1%) had suspected secondary RP, and 1,123 (37.1%) 
developed ARDs (363 UCTD, 263 SSc, 143 SLE, 24 MCTD). Suspected secondary RP 
meant patients had no clinical signs of ARD but had serological findings or abnormal 
nailfold capillaroscopy. SD pattern in capillaroscopy was significantly associated with 
development of SSc, dermatomyositis, overlap syndrome with signs of SSc and MCTD. 
The SD pattern had a better negative than positive predictive value for possible 
development of an ARD. Among the 24 patients who developed MCTD, half had 
normal capillaries, the other half had nonspecific or SD type capillary changes. The SD 
pattern was present in 9/24 (37%) patients with MCTD[48]. Another study involving 
over 1000 patients with RP reported similar findings and noted that SD type capillary 
changes with RP was indicative of the development of an ARD, despite the absence of 
other disease symptoms[49]. 
 
 In a Hungarian study[13], the number of MCTD patients with the SD pattern on 
capillaroscopy increased over time. The typical “SD pattern” at the time of diagnosis of 
MCTD (Alarcon’s criteria) was found in 31.4%. During a mean 13.1 years’ follow up, 
there was a modest progression to 40.3%. More deceased MCTD patients had SD 
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pattern compared with those MCTD patients who survived (38.3% of 258 living 
patients vs. 63.3% of 22 deceased, p<0.02). Another nailfold capillaroscopy study[50] 
performed on 63 MCTD patients (Kasukawa’s criteria) noted that SD-pattern was 
observed in 65% patients at entry and in 71.5% patients at previous capillaroscopy 
before inclusion. Capillaroscopy changed with treatment apparently, as a reduced 
capillary density was more frequently observed in patients taking immunosuppressant 
than those without medication (66.7 vs 33.3%, P= 0.001). Nailfold capillary changes in 
MCTD seem to be a dynamic process. 
 
MCTD demonstrates nailfold capillary abnormalities more reminiscent of SSc than 
SLE. But branched "bushy" capillary formations are believed by some to be 
characteristic of MCTD[25]. Despite the high frequency of RP in SLE in one study[51], 
only 2% SLE patients had an SD pattern compared with 54% of MCTD patients. A 
relationship between anti-U1RNP and Raynaud’s phenomenon was reported. 
Anti-U1RNP may contribute directly to the vasculopathy. 
 
Serology & Immunology (Table 2 summarizes new findings in recent 10 years) 
 
U1-snRNP is composed of U1-RNA, seven common core Sm proteins, and three 
U1-specific proteins (U1-70K, U1-A, and U1-C)(25). The components of the 
spliceosome complex that anti-U1snRNP recognized include the U1-RNA and the 
U1-specific polypeptides 70kD, A, and C in a study using Kasukawa’s criteria. 
Anti-U1-70K were found in 75–90% of MCTD patients (Sharp’s criteria), and were the 
most commonly detected component. They were only found in 20–50% of SLE patients 
who were positive for anti-RNP. Antibodies against the RNA component of U1-snRNP 
were found in 38% of anti-RNP positive patient sera[21],[37],[52]. 
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 Most MCTD patients have high titer anti-U1snRNP[25], but anti-U1snRNP is not 
exclusive to MCTD. In a study of 161 MCTD patients, between 20-40% of SLE patients, 
2-14% with SSc, and 6-9% with myositis were positive for anti-U1snRNP. Patients with 
RA usually lacked anti-U1snRNP antibodies[11]. IgM anti-U1snRNP titers were 
significantly higher in SLE patients than either MCTD patients (Alarcon’s criteria) or 
healthy controls (p≦0.05). IgG anti-U1snRNP was significantly higher in SLE and 
MCTD populations than in the healthy group; but IgG reactivity was similar in both 
ARDs. Combining IgM anti-U1C and anti-U1A it was possible to classify SLE and 
MCTD patients with an accuracy of 71.3%, which was rather unsatisfactory[53]. Lower 
titer anti-U1RNP were found in SLE and were usually of the IgM isotype associated 
with anti-Sm[22]. Another review[25] also reported MCTD patients were less likely 
than SLE to retain IgM U1-snRNP antibodies, and claimed that long-standing high titer 
IgG U1-snRNP are typical for MCTD conveying high specificity. This observation 
differs from the finding in the study[53] above.  
 
MCTD also differs from SLE and RA in response to another 
spliceosome-associated protein, the heterogeneous nuclear RNP (hnRNPA2). Recent 
study claimed that antibodies to Sm-D, which are present in the U1-snRNP and positive 
in 10% of white SLE patients, are largely specific for SLE. Patients who fulfill MCTD 
criteria rarely have antibodies to Sm[25]. Another cross sectional comparative analysis 
of immunological markers in sera from 51 SLE patients and 10 MCTD patients and 59 
controls reported different observations. Levels of anti-SmBB’ or anti-SmD were 
similar in SLE and MCTD sera, though antibodies to SmD were more frequent in SLE. 
Also, as sera from MCTD had higher levels of anti-U1-70kD than sera from SLE 
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patients, high anti-U1-70kDwere useful for diagnosing MCTD[54]. Notably, 94% of 
MCTD patients vs. 20% of SLE patients had sera with antibodies against U1-A 
protein[37]. 
 
Anti-U1snRNP seemed to be robust markers of MCTD onset. Their emergence 
preceded the onset of clinical manifestations[55]. Individual U1-RNP antibodies have 
been evaluated as markers of disease activity, measured by activity scales derived from 
lupus. Anti-U1-RNA titers correlated with activity, unlike anti-U1-70K titers[21].During 
remission, antibodies to U1-70K, U1-A and U1-C reduced, suggesting a correlation 
between the autoantibodies and disease activity[37]. A control study which assessed B 
cell subsets in 46 MCTD patients (Alarcon’s criteria) vs. 20 healthy individuals showed 
that anti-U1RNP levels decreased after treatment (p<0.0467)[56]. 
 
Antigen modification is important in the pathogenesis of MCTD. One study of 
alterations in post-translational modifications (PTMs) on U1snRNP 68k subunit in 4 
MCTD, 4 SLE, 4 RA patients and 3 healthy donors showed that MCTD and SLE 
patients were characterized by increase of low phosphorylated U1-68k. PTMs on 
autoantigens were involved in the production of antibodies as altered self-proteins 
created novel epitopes to which the immune system has not been tolerized[57].The 
70kD polypeptide of U1-RNP is susceptible to multiple forms of antigen modification 
including PTM and caspase cleavage during apoptosis or oxidative cleavage in response 
to stress. Apoptotically modified 70kD is antigenically distinct from intact 70kD and 
may have clinical implications in breaking immune tolerance. Autoantibodies reactive 
with apoptotic 70kD are superior markers to those against intact 70kD for 
MCTD[21],[55]. In 53 MCTD patients, 29(54%) preferentially recognized the apoptotic 
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form of 70K compared to intact 70K[31]. The appearance of autoantibodies to 
U1-snRNP components follows a characteristic order. Antibodies to U1-70K and 
Sm-B/BV generally appear early. Anti-U1A and U1C and Sm-D are detected later. 
U1-70K is a major early immunogen, this together with the fact that U1-70K is 
modified during apoptosis, suggest apoptotic modifications on U1-70K protein might be 
important for triggering immune response to U1snRNP[58]. 
 
A cohort study evaluated 15 peptides in 68 SLE and 29 MCTD patients and 26 
healthy individuals. U1-70K was the best at predicting which samples were in the SLE 
group from healthy samples and the second best at separating MCTD from healthy 
samples (p=0.0001). Another two peptides from U1A protein, were the 2 best predictors 
of SLE vs. MCTD (p=0.167 and p=0.206). Though they are not capable of definitively 
segregating SLE from MCTD,U1A may be the most likely protein that can distinguish 
the 2 diseases[59]. 
 
 There are 2 proposed mechanisms of pathogenic role by anti-U1RNP:  
1) Binding to endothelial cells, leads to endothelial cell activation and damage leading 
to vascular disease pathogenesis, inducing RP, puffy hands, sclerodactyly, PH, possibly 
ILD and esophageal dysmotility.  
2) Forming immune complexes that might activate complement, induce myositis, 
(non-erosive) arthritis and perhaps ILD. The pathogenesis of erosive arthritis is 
unclear[22]. 
 
A recent study reported that the proportion of transitional B cells, naive B cells and 
double negative (DN) B lymphocytes was higher in MCTD patients (Alarcon’s criteria) 
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than in controls. The memory B cell population had a close correlation with disease 
activity measured by the systemic lupus activity measure (SLAM). The number of 
plasma cells was also increased and there was an association between their number and 
anti-U1RNP levels. Cyclophosphamide, methotrexate, and corticosteroid treatment 
decreased the number of DN and CD27high B cells[56]. 
 
In a cross-sectional study involving 21 MCTD patients (Alarcon-Segovia’s criteria), 
CD4+CD25high T regulatory cells decreased with increasing levels of disease activity, 
though the correlation was not significant[60]. In another study of T regulatory (Treg) 
cells involving 48 MCTD patients(Alarcon-Segovia’s criteria), the percentage and 
absolute number of CD4+CD25+high Treg cells were lower in the MCTD patients than 
in controls (p<0.04), and were further decreased in active MCTD and lower than in the 
inactive stage (p<0.01). There was an increase in percentage and absolute number of 
CD4+IL-10+ Treg cells in MCTD patients compared to the healthy controls (p<0.02). 
The percentage of CD4+IL-10+ Treg cells was higher during active disease than during 
remission (p<0.005). The role of these cells in immunoregulation and inflammation is 
reviewed elsewhere[61]. 
 
Immune mechanisms that contribute to U1-snRNP immunogenicity include epitope 
spreading through B and T-cell interactions and apoptosis induced modifications. 
Spread of immunogenicity can occur within a single antigen to multiple epitopes on the 
same protein (intramolecular spreading) or to other epitopes within a greater 
macromolecular complex (intermolecular epitope spreading)[37]. 
 
Genetics  
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 Novel genetic associations within the major histocompatibility complex (MHC) on 
chromosome 6 and select regions on chromosome 3 have been claimed for MCTD. The 
frequency of HLA-DR4 was increased in MCTD compared to healthy controls in 
world-wide population-based studies. In MCTD patients, no association was found with 
MHC haplotypes associated with SLE (HLA-DR3) or scleroderma (HLA-DR5)[55]. A 
significant association of U1RNP disease with HLA-DR4 and DR154–61 was noted, 
which was different from SLE or SSc[22]. Thus HLA evidence seems to favour MCTD 
being distinct from other ARDs, and as a disease that is T-cell dependent, given the 
HLA class II association. In contrast, other evidence implied HLA-DR4 seemed 
primarily to be related to U1-RNP antibody formation rather than disease expression. 
Patients with or without MCTD did not differ with respect to DR4 frequency. In these 
studies, some allotyped MCTD patients used SLE patients as controls, while others used 
healthy individuals. In certain studies, the MCTD patients exhibited a heterogeneous 
clinical picture with a few fulfilling the classification criteria for SLE or SSc. The 
classification criteria for recruiting MCTD patients also varied with Sharp’s and 
Alarcon-Segovia’s criteria being used in different studies. Thus the claims made about 
the association of MCTD with HLA-DR4 remain confused[25]. 
 
Treatment 
 
In the past decade there has been a lack of randomized trials. Management relies on 
extrapolation of guidelines for equivalent manifestations in SLE; SSc and RA.  
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Immunosuppressive therapy and steroids remain thetherapeutic mainstay for 
MCTD. A retrospective study of 161 patients with MCTD showed that 58% required 
aggressive immunosuppression and only 3% achieved disease control using symptomatic 
therapies[11]. 
  
The use of anti-TNFαin MCTD with refractory erosive arthritis, was assessed in a 
prospective study of 280 patients. 44(17.5%) were diagnosed with erosive arthritis, all 
except two were treated with methotrexate plus anti-TNFα drug[13]. No adverse effects 
were reported. However, the experience with its use is limited and there are case reports 
that anti-TNFα was associated with development of an SLE like syndrome[62]. 
  
The treatment of PAH associated with MCTD is complex. General measures 
(oxygen suply, diureticsetc.) are usually insufficient and invariably more aggressive 
treatment with prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 
inhibitors are needed to improve pulmonary functional status[13].  
 
Surgical options are the alternative for those patients who continue to progress 
despite aggressive therapy. They include procedures like atrial septostomy and lung 
transplantation[26].  
 
Prognosis  
 
The initial notion of MCTD being a benign disease was abandoned after many 
studies showing that most patients did not have favourable outcome. 
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Lundberg and colleagues reported that 1/3 of patients with MCTD had a benign 
course, 1/3 had an aggressive course and 1/3 improved with immunosuppressive therapy 
but required it for several years[43]. However, the small number of long term outcome 
studies limits our knowledgeinmorbidity and mortality in MCTD patients. 
  
The principal causes of morbidity in first years of MCTD were RP and esophageal 
hypomotility. Sclerodactyly, diffuse sclerosis, PAH and nervous system disease are 
major causes of morbidity in long-term MCTD patients[43].  
 
In a recent study, 12 of the 147 (8.2%) patients died after followed up for a mean 
of 5.6 years. Three of the five patients having PH died from right ventricular failure. In 
the other 9 deceased patients, the causes of death were ILD (n=2); coronary heart 
disease (n=2), cancer (n=4) and unknown (n=1)[17]. 
  
A prospective study of 280 patients found a survival of 98% at 5 years; 96% at 10 
years and 88% at 15 years[13]. Twenty two (7.8%) patients died. In 12 out of 22, the 
causes of death were directly related to MCTD manifestations. Ten patients died as a 
result of complications from MCTD.  
  
The presence of cardiovascular events, esophageal hypomotility, serositis, 
secondary antiphospholipid syndrome and malignancy was significantly higher in the 
deceased patients. Also, the presence of ACL, anti-β2-GPIand AECA increased the risk 
of mortality[13]. 
 
Conclusion 
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In Table 3 a comparison is shown of the original features said to have 
distinguished MCTD and the features currently claimed to constitute the condition. It 
shows that a major evolution in the concept has occurred.  
 
Some evidence implying that MCTD does ‘exist’ as an entity has emerged from 
genetic studies, but the genetic association is actually not very consolidated. There are 
data showing that components of U1-snRNP are important for triggering immune 
responses and that anti-RNP has a central pathogenic role and may contribute to disease 
manifestations.  
 
Nevertheless there is no evidence that >40% of patients given a diagnosis of 
SLE/ RA/ Sjogren’s change their clinical features to become recognized as another ARD 
analogous to MCTD. We postulate that different forms of antigen modification and 
epitope spreading together with B and T-cell interactions may have implications in 
disease evolution to other ARDs. Thus we continue to question whether the term MCTD 
is appropriately retained, preferring to use the term “undifferentiated autoimmune 
rheumatic disease”. 
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Table 1: New Findings in Clinical Features of MCTD in Recent 10 Years 
Clinical Features of Mixed Connective Tissue Disease (MCTD) 
 
References Observations Comments 
General 
 
- Cappelli S et al.[11] 
2012 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General 
 
-After a mean of 7.9 years, 57.9% patients still 
satisfied Kasukawa’s criteria 
 
-Patients >5 years of disease more frequently 
evolved into other ARDs.  
 
- Kasukawa’s criteria were more sensitive than 
Alarcón-Segovia’s and Sharp’s criteria. 
 
-Anti-DNA was associated with evolution into 
SLE; esophageal abnormality and sclerodactyly 
with evolution into SSc. 
 
-Clinical features of MCTD may evolve from 
inflammatory phase to sclerotic phase. 
 
General 
 
-Retrospective review of 161 MCTD 
patients at time of diagnosis and in 
2008 for evolution.  
 
- Hajas A et al.[13] 
2013 
 
-During FU new symptoms developed; but 
patients didn’t show progression to other ARDs. 
 
-Prospective FU of 280 MCTD 
patients diagnosed between 1979 & 
2011. 
 
- Gunnarsson R et al.[12] 
2011  
-Prevalence of living adult MCTD patients in 
Norway = 3.8 (95% CI 3.2-4.4) per 100 000.  
 
-Incidence of adult-onset MCTD in Norway from 
1996-2005 = 2.1 (95% CI 1.7-2.5) per million 
per year. 
 
-The point prevalence showed no statistical 
difference between the 3 classification criteria. 
 
-Nationwide cross-sectional 
retrospective study of 147 patients 
investigating the prevalence and 
incidence of MCTD. 
 
 
Pulmonary 
hypertension (PH): 
 
-Hajas A et al.[13] 
2013  
 
Pulmonary hypertension: 
 
 
-50 of 280 (17.9%) patients developed PAH 
14.5±3.71 yrs after MCTD diagnosis. 
 
Pulmonary hypertension: 
 
 
-Prospective FU of 280 MCTD 
patients diagnosed between 1979 & 
2011. 
 
- Gunnarsson R et al.[17] 
2013 
 
-PH frequency was 3.4% in MCTD (5/147). 2 
had isolated PAH & 3 had PH associated with 
ILD. 
 
-Nationwide multicentre cohort of 147 
adult MCTD patients screened for PH 
with mean FU of 5.6 years. 
 
- Vegh J et al.[18] 
2006  
 
 
-25 of 179 MCTD patients (14%) developed 
PAH. Interval between MCTD diagnosis and 
PAH was 8.4+/-4.1 yrs 
 
-5-year survival was lower in 25 MCTD-PAH 
than in 154 MCTD-non-PAH patients (73% vs 
96%;P<0.01). 
 
-AECA were more frequently present in MCTD-
PAH than in MCTD-non-PAH patients 
(P<0.001).  
 
-Levels of anti-U1RNP were higher in MCTD-
PAH than in MCTD-non-PAH patients (56.2+/-
-FU of 179 MCTD patients & 
compared those who developed PAH 
with those who didn’t. 
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19.4 U/ml vs 26.08+/-18.4 U/ml; P<0.001). 
 
-Accumulated damage index was higher in 
MCTD-PAH than in MCTD-non-PAH patients 
(30.6+/-6.8 vs 27.6+/-4.4;P<0.001). 
 
- Jeon CH et al.[23]  
2012 
 
 
 
 
 
 
 
 
 
-In 321 ARD-PAH patients, SLE accounted for 
35.3%, SSc 28.3%, RA 7.8%, overlap syndrome 
9.0%, and MCTD 5.9%.  
 
-No significant differences in hemodynamics, 
functional class & diffusing capacity between the 
disease subgroups. Mean sPAP level was higher 
in SLE-PAH than in SSc-PAH or MCTD-PAH. 
 
-PAH in MCTD is more commonly associated 
with Raynaud’s syndrome, abnormal 
capillaroscopy. 
 
-Cohort of 321 ARD patients who had 
WHO group I PAH diagnosed from 
2008-2010. 
 
- Hajas A et al.[13] 
2013  
 
- Szodoray P et al.[33] 
2012 
 
- Hasegawa E et al.[20] 
2009 
-Anti-U1RNP, AECA & ACL were associated 
with PAH. Anti-U1RNP increased surface 
expression of adhesion molecules on pulmonary 
artery endothelial cell in vitro. 
 
 
-Mean IgG anti-β2-GPI was higher among 
MCTD patients with PAH than in those without 
(34.2±46.8 vs 12.3±9.1, P=0.018). 
 
-See above  
 
-Cluster analysis of 201 MCTD 
patients followed up longitudinally 
 
 
-Prospective analysis of 
antiphopholipid antibodies in 39 
MCTD patients and 21 controls. 
 
Interstitial lung disease 
(ILD):  
 
- Hajas A et al.[13] 
2013  
 
 
 
 
Interstitial lung disease (ILD):  
 
 
-132/280 (47.1%) MCTD patients had ILD. 
 
-Most frequent symptoms were polyarthritis 
(89.6%), Raynaud’s (57.5%), ILD (47.1%) & 
esophageal dysmotility (49.6%). 
Interstitial lung disease (ILD):  
 
 
-Prospective FU of 280 MCTD 
patients diagnosed in 1979-2011. 
- Gunnarsson R et al.[29] 
2012   
-52% of 126 MCTD patients had abnormal 
HRCT consistent with lung fibrosis (35%). Lung 
fibrosis was quantified as minor in 7%, moderate 
in 9% and severe in 19%. 
 
-Patients with severe lung fibrosis had poorer 
lung functions, shorter 6MWT and higher mean 
NYHA functional class. After a mean 4.2yrs, 
overall mortality was 7.9%. Mortality with 
normal HRCT was 3.3% vs 20.8% with severe 
fibrosis (p<0.01) 
 
-24 patients with severe lung fibrosis were older, 
had shorter mean disease duration (6.4 years) 
than minor or moderate fibrosis (13.2 years) 
 
-Systemic examination of 126 MCTD 
patients for ILD. 
- Szodoray P et al.[33] 
2012  
-3 different sub-phenotypes of MCTD: 
1st subgroup: AECA and antiphospholipid 
antibodies in association with PAH, Raynaud’s, 
livedo reticularis and vascular thrombosis. 
2nd subgroup: ILD, esophageal dysmotility and 
myositis. 
3rd subgroup: higher prevalence of anti-CCP and 
erosive arthritis 
 
-In cluster 2, the incidences of ILD (98.7%), 
myositis (77.2%), and esophageal dysmotility 
-Longitudinal FU and cluster analysis 
of 201 MCTD patients. 
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(89.8%) were significantly greater than in cluster 
1 and 3 (p<0.001). No patients with ILD had 
positive anti-Jo1.  
 
-Immune complex formation and complement 
were associated with ILD and myositis. 
 
-Worst overall survival probability was in cluster 
1 (vascular damage), followed by cluster 2 (ILD, 
myositis), the best survival was in cluster 3 
(arthritis) 
 
- Fagundes MN et al.[30] 
2009  
 
-HRCT abnormalities were present in 39/50 
patients. The presence of ILD was significantly 
higher among patients with esophageal dilatation 
(92% vs. 45%;p<0.01) and esophageal motor 
dysfunction (90% vs. 35%;p<0.001). 
 
-No statistically significant differences in ILD 
between patients with normal and abnormal acid 
reflux.  
 
-Correlation between diffusing capacity and ILD, 
but not between total lung capacity and ILD. 
 
-Evaluation of the relationship 
between esophageal dysfunction and 
ILD in 50 MCTD patients 
 
- Hof D et al.[31] 2005 
 
 
 
-Anti-U1RNP may have pathogenic role by 
interacting with lung tissue. 
-Cross sectional & longitudinal study 
of 53 MCTD patients tested positive 
for anti-U1snRNP and anti-70K. 
 
Esophageal involvement 
 
- Fagundes MN et al.[30] 
2009  
 
 
 
 
 
 
 
 
Esophageal involvement 
 
-Esophageal dilatation, gastroesophageal reflux, 
and esophageal motor impairment were very 
prevalent (present in 28/50, 18/36, and 30/36 
patients, respectively). 
 
-36 patients underwent esophageal manometry: 
normal (n=6/36;16.7%); moderate dysfunction 
(n=7/36;19.4%); and severe dysfunction 
(n=23/36;63.9%).  
 
-36 patients had 24-hour pH measurements: 18 
(50%) had distal abnormal acid reflux, 6 (16%) 
had proximal acid reflux. Severe esophageal 
dysfunction (aperistalsis) on manometry was not 
significantly related to proximal (p=0.38) or 
distal reflux (p=0.16) 
 
Esophageal involvement 
 
-Evaluation of relationship between 
esophageal dysfunction and ILD in 50 
MCTD patients 
 
- Caleiro MTC et al.[34] 
2006  
-Association between abnormalities in 
pulmonary function & esophageal dysfunction in 
radionucleotide scintigraphy showing significant 
delay in the clearance of the nucleotide. 
 
-Assessment of esophageal motility 
disorder in 24 MCTD patients vs 11 
healthy individuals.  
 
Arthritis 
 
- Mimura Y et al.[35] 
2006 
 
 
 
Arthritis 
 
-Serum IgM-, IgG- and IgA-RF in MCTD were 
significantly higher than controls. (mean±SD: 
3.61±4.71 vs 0.75±0.54, p<0.05; 1.35±0.96 vs 
0.52±0.39, p<0.001; and 2.26±2.83 vs 0.62±1.24, 
p<0.0005).  
 
-Frequency of IgM-RF in MCTD patients was 
48%, lower than in RA patients (77%). 
Frequency of IgG-RF in MCTD was 38%, 
compared to RA (25%). The frequency of IgA-
RF in MCTD was 33%, lower than in RA (53%). 
Arthritis 
 
-Longitudinal analysis of levels of RF 
isotypes in 21 MCTD patients and 14 
controls. 
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Cardiovascular  
involvement 
 
- Végh J et al.[24] 
  2006  
 
 
 
 
 
 
 
 
 
 
 
Cardiovascular involvement 
 
 
-Diastolic dysfunction of left ventricle was 
detected in MCTD. Diastolic Ee/Aa velocity 
quotient was lower (p<0.01), mean deceleration 
time was longer (p<0.001) than control group. 
Tei index demonstrated damage of the global 
ventricle function.  
 
-Tei index of the right ventricle indicated global 
failure of the right ventricle in cases of MCTD 
with PAH (Tei index 0.36±0.07 in MCTD with 
PAH vs. 0.28±0.04 without, p<0.001). Right 
ventricle function of MCTD patients without 
PAH was no different from controls. 
Cardiovascular involvement 
 
 
-Cross-sectional study of right and left 
ventricle functions in 51 MCTD 
patients & 30 healthy controls. 
 
 
 
 
 
 
 
 
 
 
- Soltesz P et al.[42] 
2010   
 
 
-Flow-mediated dilation (FMD) was significantly 
impaired in MCTD vs controls (%FMD: 
4.7±4.2% vs. 8.7±5.0%; P<0.001). 
 
-FMD negatively correlated with disease 
duration, apolipoprotein A1 levels, paraoxonase-
1 activity, and systolic blood pressure in MCTD. 
 
-% FMD was significantly lower in MCTD with 
cardiovascular diseases (CVD), than in those 
without (%FMD: 3.5±2.9 vs.5.8±4.8, P<0.0002). 
 
-% nitrate-mediated dilation (NMD) did not 
differ between MCTD vs controls (14.3±6.6% 
vs. 17.1±6.7%; P=0.073), and patients with or 
without CVDs. 
 
-Mean carotid intima-media thickness was higher 
in MCTD than in controls (0.64±0.13 mm vs. 
0.53±0.14 mm; P<0.001). 
 
-Anti-U1RNP, AECA and ACL were 
significantly higher in MCTD and differed 
between MCTD with and without CVD.  
 
-Endothelial cell markers such as soluble 
thrombomodulin (12.2±8.1 ng/ml vs. 3.2±1.3 
ng/ml;P<0.001) & vWFAg (224.1±115% vs. 
89.4±27.1%;P<0.001) were the highest in MCTD 
with CVD. 
 
-FU study of 50 MCTD patients and 
38 controls to investigate association 
between cardiovascular risk factors & 
endothelial dysfunction. 
Renal involvement 
 
- Pope JE.[36] 2005 
 
 
Renal involvement 
 
-40% of MCTD patients had renal involvement 
including glomerulonephritis, nephrotic 
syndrome, scleroderma renal crisis 
 
-MCTD patients with renal disease had more 
systemic manifestations than those without. 72% 
of the nephropathy patients had resolution or 
improvement with steroid. 
 
-Electron microscopy revealed immune complex 
deposition in the glomeruli. 
 
Renal involvement 
 
-Review of other manifestations in 
MCTD. 
- Lundberg IE.[43] 2005 
 
-Renal involvement occurred with frequency 
between 5% and 36%. 
-Review of MCTD. 
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- Greidinger EL et al.[46] 
2006 
 
 
-Immunization of mice with RNP antigen 
induced anti-RNP and MCTD manifestations, 
(ILD but not renal disease); but for mice 
deficient in Toll-like receptor 3, RNP antigen 
exposure induced SLE-like nephritis 
. 
-Case series and immunization study 
of murine models 
RP & capillaroscopy 
 
- Pavlov-Dolijanovic S 
et al.[48] 2012  
 
 
 
 
 
 
 
Raynaud’s phenomenon (RP) & 
capillaroscopy 
 
-At the end of FU, 1,660 (54,8%) patients still 
had primary RP, 246 (8,1%) had suspected 
secondary RP, and 1,123 (37,1%) developed 
ARDs (363 UCTD, 263 SSc, 143 SLE, 24 
MCTD) 
 
-Mean time interval from RP to diag of ARD 
=6.2 yrs 
 
-Scleroderma (SD) pattern in capillaroscopy 
were significantly associated with development 
of SSc(P=.00001), dermatomyositis(P=.0004), 
overlap syndrome with signs of SSc(P=.0001), 
and MCTD(P=.007). 
 
-Half of MCTD patients had normal capillaries, 
other half had nonspecific or SD type capillary 
changes. No patients with SSc or  
dermatomyositis showed normal capillaries.  
 
-SD pattern was present in 246/263 (94%) 
patients with SSc, in 5/7 (71%) with 
dermatomyositis, in 28/61 (46%) with overlap 
syndrome (all patients with SD pattern had signs 
of  SSc), and in 9/24 (37%) with MCTD. 
 
-All patients with primary RP and most patients 
with RA (88%), UCTD (82%), Sjögren’s 
syndrome (82%), SLE (75% )had normal 
capillaries. 
 
-SD type nailfold capillary changes had better 
negative than positive predictive value for 
development of ARD. SD changes can predict 
future development of ARD. OR ratio for 
development of SSc in those with SD type 
capillary abnormality was 163, dermatomyositis 
(OR 13.67), overlap syndrome with signs of SSc 
(OR 4.83), and MCTD (OR 3.30). 
 
RP & capillaroscopy 
 
-Prospective outcome study of 3,029 
patients with diagnosis of primary RP 
FU for a mean of 4.8 yrs. 
 
- Meli M et al.[49]  
2006 
 
-Presence of SD type capillary changes with RP 
is indicative of future development of ARD, even 
in the absence of other disease symptoms. 
 
-Capillaroscopy alone or combined 
with fluorescence videomicroscopy 
study of 1024 patients with RP. 
- Hajas A et al.[13]  
2013  
 
-Capillaroscopy showed gradual progression of 
vascular abnormalities. “Scleroderma pattern” at 
the time of diagnosis of MCTD was noted in 
31.4% of patients, after 13.1 years’ FU there was 
a weak progression (40.3%; p<0.03). 99/258 
(38.3%) living patients vs. 14/22 (63.3%) 
deceased patients had SD-pattern (p<0.02). 
 
-Prospective FU of 280 MCTD 
patients diagnosed in 1979-2011 in 
Hungarian population. 
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- de Holanda Mafaldo  
Diogenes A et al.[50] 
  2007  
 
 
 
 
 
 
 
 
 
 
 
 
-SD-pattern was observed in 41 patients at entry 
(65%) and in 45 at previous capillaroscopy 
(71.5%), P=0.20. 10 patients (16%) had changed 
capillaroscopy. Disease duration, number and 
frequency of organ involvement were similar in 
patients with and without SD-pattern. 
 
-Reduced capillary density was more frequently 
observed in patients taking immunosuppressants 
than those without medication (66.7 vs 33.3%, 
P=0.001).  
 
-Nailfold capillaroscopy in MCTD is a dynamic 
process. Analysis of SD-pattern parameter may 
be good indicator of disease severity. 
 
-Nailfold capillaroscopy was 
performed 5 years preceding inclusion 
& at least 18 months after 1st study 
evaluation of 63 MCTD patients. 
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Table 2: New Findings in Immunology & Genetic Aspects of MCTD in Recent 10 Years 
Serology & Immunology of Mixed Connective Tissue Disease (MCTD) 
 
References Observations Comments 
- Cappelli S et al.[11]  
2012 
 
 
 
- Mesa A et al.[53]  
2013 
 
 
 
 
 
 
 
 
 
-Salmhofer W et al.[54]  
2007 
 
-Anti-U1snRNP are not confined to MCTD. 20%-
40% of SLE patients, 2-14% with SSc, and 6%-
9% with myositis are anti-U1snRNP positive. RA 
patients are generally negative.  
 
-IgM anti-U1snRNP titers were significantly 
higher in SLE than in MCTD or healthy 
individuals(p≦0.05). IgG anti-U1snRNP were 
significantly higher both in SLE and MCTD than 
in healthy group; but IgG reactivity does not 
differ between two ARDs. 
 
-Combining IgM anti-U1C and anti-U1A is 
capable of classifying SLE and MCTD patients 
with an accuracy of 71.3%.  
 
-MCTD showed higher levels of anti-RNP-70kD 
than SLE. Levels of anti-SmBB’ or anti-SmD 
were not significantly different between SLE and 
MCTD. High anti-RNP-70kD is useful for 
diagnosing MCTD. 
-Retrospective study of 161 MCTD 
patients at time of diagnosis and in 
2008 for evolution.  
 
 
-Study of IgM- and IgG-mediated 
responses against U1snRNP 
subunits in 81 SLE, 41 MCTD 
patients & 31 healthy individuals. 
 
 
 
 
 
 
 
-Cross sectional comparative 
analysis of immunological markers 
in 51 SLE and 10 MCTD patients 
and 59 controls. 
 
- Hajas A et al.[56] 
2013 
 
 
 
 
-Anti-U1RNP levels decreased after treatment 
(p<0.0467). The most effective drug was 
cyclophosphamide. Methotrexate and 
methylprednisolone decreased antibody levels, 
but not significantly. 
 
-Study of B cell subsets in 46 
MCTD vs 20 healthy individuals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Proportion of transitional B cells, naive B cells 
& double negative (DN) B lymphocytes was 
higher in MCTD than in controls. The memory B 
cells level showed close correlation with disease 
activity. The number of plasma cells was 
increased; their number was associated with anti-
U1RNP levels. Cyclophosphamide, methotrexate, 
and corticosteroid decreased the number of DN 
and CD27 high B cells. 
 
 
 
 
 
 
 
 
 
- Maldonado ME et al.[60] 
 2008 
 
 
- Baráth S et al.[61]  
2006 
-In MCTD, CD4+CD25high cells decreased with 
increasing levels of disease activity measured by 
SLEDAI (r2=0.11).  
 
-The % and absolute number of CD4+CD25+high 
Treg cells were lower in MCTD patients than in 
healthy controls (p<0.04), and were further 
decreased in active MCTD compared with 
inactive stage (p<0.01). There’s an increase in % 
and absolute number of CD4+IL-10+Treg cells in 
MCTD patients compared to controls (p<0.02). 
Their % was higher in active than in inactive 
stage (p<0.005).  
 
-Cross-sectional study of 21 MCTD 
& 39 SLE patients from Miami and 
Missouri Caucasian cohorts. 
 
-Cross sectional study of % and 
absolute number of CD4+ 
regulatory T-cells (Treg) in 48 
MCTD patients. 
 
- Nagai K et al.[57] 
2012 
 
 
 
-MCTD and SLE are characterized by increase of 
low phosphorylated U1-68k. Post-translational 
modifications on autoantigens are involved in the 
production of autoantibodies. 
 
-Study of antigen modification on 
U1snRNP 68k subunit, a major 
antigen of anti-RNP in 4 MCTD, 4 
SLE, 4 RA patients and 3 healthy 
individuals. 
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- Hof D et al.[31] 
2005 
 
 
-29/53 (54%) MCTD sera preferentially 
recognize apoptotic form of 70K over intact 70K. 
Antibodies directed to apoptosis-specific epitope 
on 70K are more specifically associated with 
MCTD. 
 
 
-Cross sectional & longitudinal 
study of 53 MCTD patients positive 
for anti-U1snRNP and anti-70K. 
- Somarelli J et al.[59]  
2011 
-From epitope mapping, most of the U1snRNP 
antigenic sites reside on the surface of the 
complex. 
 
-Most of the peptides from U1snRNP are mildly 
to moderately antigenic. The 2 most antigenic 
peptides are from U1C protein while the least 
antigenic is from U1A protein. 
 
- U1-70K is the best at segregating SLE from 
healthy samples and the second best at separating 
MCTD from healthy samples (p=0.0001). 
 
- Peptides 1 and 13 from U1A protein, are the 2 
best predictors of SLE vs. MCTD (p=0.167 and 
p=0.206). Though they’re not capable of 
significantly segregating SLE from MCTD. 
 
-Cohort study of 15 peptides on 
U1snRNP structure in 68 SLE, 29 
MCTD patients and 26 healthy 
individuals. 
- Hasegawa E et al.[20] 
2009 
 
 
 
-Medium to high titres of ACL & anti-β2-GPI 
were found in 4/39 (10.2%) MCTD patients. High 
to moderate titres of anti-β2-GPI & APS were 
rare in MCTD. 
 
-Prospective analysis of 
antiphopholipid antibodies in 39 
MCTD patients and 21 controls.  
Genetic Aspects of MCTD 
 
References Observations Comments 
- Hoffman RW et al.[55] 
  2008   
 
 
 
 
 
 
 
 
- Aringer M et al.[22]  
2007 
 
 
 
 
 
- Aringer M et al.[25] 
2005 
 
 
-Novel genetic associations within the MHC on 
chromosome 6 and select regions on chromosome 
3 were identified for MCTD.  
 
-Frequency of HLA-DR4 is increased in MCTD 
compared to healthy controls. In MCTD, no 
association was found with MHC haplotypes 
associated with SLE (HLA-DR3) or SSc (HLA-
DR5). 
 
-Significant association of U1RNP-associated 
disease with HLA-DR4 and DR154–61, which is 
different from SLE or SSc. HLA class II 
molecules might influence clinical phenotype as 
carrying HLA-DR3 leads to higher risk for lung 
fibrosis. 
 
-HLA evidence in favour of MCTD as distinct 
disease from SLE, SSc, or PM/DM, and as 
disease that is T-cell dependent, given the HLA 
class II association. 
 
-Review of immune pathogenesis of 
MCTD. 
 
 
 
 
 
 
 
 
-Review of MCTD. 
 
 
 
 
 
 
-Review of MCTD. 
 
 
   
